A formulation to treat ocular conditions such as dry eye disease, as well as other conditions, is disclosed. Rapamycin and/or ascomycin is administered intraocularly, such as by topical application, injection into the eye, or implantation in or on the eye. For example, a topical administration may contain between about 50 pg/ml drug to about 50 .mu.g/ml drug in a formulation which may be applied at bedtime or throughout the day. For injection, a dose of about 50 pg/ml to about 200 .mu.g/ml may be used. Rapamycin and/or ascomycin may also be administered in milligram quantities as a surgical implant, for example, in a diffusible walled reservoir sutured to the wall of the sclera, or may be contained within an inert carrier such as microspheres or liposomes to provide a slow-release drug delivery system.

 
Web www.patentalert.com

< Transgenic corn plants having seeds with modified cornstarch characteristics and method of making the transgenic corn plants

< Functional coupling of T1Rs and T2Rs by Gi proteins, and cells-based assays for the identification of T1R and T2R modulators

> Enhanced oil seed protein recovery

> Natural herbicide resistance in wheat

~ 00281